Halil Ibrahim Aydin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Halil Ibrahim Aydin has a total of 355 co-authors. Here are the top co-authors by number of shared publications:
Metin Denli
4 shared publications- Ruşen Dündaröz
Department of Pediatrics, Gülhane Military Medical Academy and Medical School, Ankara, Turkey
4 shared publications - Çiğdem Seher Kasapkara
Ankara Yildirim Beyazit University
4 shared publications - Banu Kadıoğlu Yılmaz
Department of Pediatric Nutrition and Metabolism, Faculty of Medicine, Selçuk University, Konya 42250, Türkiye
3 shared publications - Burcu Ozturk Hismi
School of Medicine, Marmara University
3 shared publications Erdal Gokcay
Department of Pediatrics Division of Pediatric Nephrology Department of Clinical Biochemistry Gülhane Military Medical Academy & Medical Faculty Ankara Türkiye
3 shared publications
Latest Publications
- 15 October 2026
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 185 (11) , 853
Diagnostic timing in cerebral creatine deficiency syndromes: neurodevelopmental and genetic characterization of a multicenter cohort
- 15 October 2026
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 185 (11) , 853
Diagnostic timing in cerebral creatine deficiency syndromes: neurodevelopmental and genetic characterization of a multicenter cohort
- 2 October 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (10) , 833
Clinical spectrum and genetic landscape of MTHFR deficiency: a cohort study including novel variants
- 2 October 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (10) , 833
Clinical spectrum and genetic landscape of MTHFR deficiency: a cohort study including novel variants
- 21 May 2026
- Published by Springer Nature in European Journal of Clinical Nutrition
- Vol. 80 (8) , 763-771
Evaluation of food rejection and swallowing function in inherited metabolic diseases on diet therapy
Feeding difficulties and swallowing dysfunction are common clinical problems in children with inherited metabolic diseases (IMDs); however, evidence in the literature remains limited. This cross-sectional study aimed to evaluate food refusal and swallowing function in children with IMDs receiving diet therapy and to investigate their relationship with malnutrition risk. This cross-sectional study included 49 children aged 2-6 years diagnosed with carbohydrate (30.6%) and protein (69.4%) metabolism disorders. The STRONGkids tool was used to evaluate malnutrition risk, while nutritional classification was based on WHO-derived anthropometric Z-scores. Swallowing function was assessed using the Pedi-EAT-10, and food refusal behaviors were evaluated with the Food Refusal Scale. Sociodemographic characteristics, dietary habits and anthropometric measurements were recorded. Logistic regression analysis was performed to determine independent predictors of high malnutrition risk. According to STRONGkids results, 85.7% of the participants were at moderate risk and 14.3% were at high risk of malnutrition. Higher Pedi-EAT-10 scores were significantly associated with early complementary feeding, prolonged feeding duration, extended total daily feeding time, and reported feeding difficulties (p < 0.05). Logistic regression analysis demonstrated that Pedi-EAT-10 (OR: 1.125; 95% CI: 1.025-1.236; p = 0.013), selectivity (OR: 1.241; 95% CI: 1.110-1.645; p = 0.044), and neophobia (OR: 1.430; 95% CI: 1.117-1.829; p = 0.005) were independently associated with high malnutrition risk. Food refusal behaviors and swallowing dysfunction are significantly associated with malnutrition risk in children with IMDs. Comprehensive assessment of feeding behavior and swallowing function may facilitate early identification of nutritional vulnerability and support individualized dietary management strategies.
- 21 May 2026
- Published by Springer Nature in European Journal of Clinical Nutrition
- Vol. 80 (8) , 763-771
Evaluation of food rejection and swallowing function in inherited metabolic diseases on diet therapy
Feeding difficulties and swallowing dysfunction are common clinical problems in children with inherited metabolic diseases (IMDs); however, evidence in the literature remains limited. This cross-sectional study aimed to evaluate food refusal and swallowing function in children with IMDs receiving diet therapy and to investigate their relationship with malnutrition risk. This cross-sectional study included 49 children aged 2-6 years diagnosed with carbohydrate (30.6%) and protein (69.4%) metabolism disorders. The STRONGkids tool was used to evaluate malnutrition risk, while nutritional classification was based on WHO-derived anthropometric Z-scores. Swallowing function was assessed using the Pedi-EAT-10, and food refusal behaviors were evaluated with the Food Refusal Scale. Sociodemographic characteristics, dietary habits and anthropometric measurements were recorded. Logistic regression analysis was performed to determine independent predictors of high malnutrition risk. According to STRONGkids results, 85.7% of the participants were at moderate risk and 14.3% were at high risk of malnutrition. Higher Pedi-EAT-10 scores were significantly associated with early complementary feeding, prolonged feeding duration, extended total daily feeding time, and reported feeding difficulties (p < 0.05). Logistic regression analysis demonstrated that Pedi-EAT-10 (OR: 1.125; 95% CI: 1.025-1.236; p = 0.013), selectivity (OR: 1.241; 95% CI: 1.110-1.645; p = 0.044), and neophobia (OR: 1.430; 95% CI: 1.117-1.829; p = 0.005) were independently associated with high malnutrition risk. Food refusal behaviors and swallowing dysfunction are significantly associated with malnutrition risk in children with IMDs. Comprehensive assessment of feeding behavior and swallowing function may facilitate early identification of nutritional vulnerability and support individualized dietary management strategies.
- Open Access
- 20 June 2025
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 55 (3) , 585-594
Expert opinion on clinical presentation, diagnosis and treatment of infantile onset pompe disease: a delphi study in Türkiye
Background/aim: Pompe disease (acid maltase deficiency, glycogen storage disease type II, OMIM #606800) is an autosomal recessive disorder characterized by lysosomal acid-α-glucosidase deficiency. The infantile-onset type of the disease is mainly characterized by cardiomegaly, hypotonia, and a high mortality rate. This study aimed to create a national consensus about infantile-onset Pompe disease (IOPD) to raise awareness among clinicians and standardize diagnosis and treatment approaches in Türkiye. Materials and methods: The Gazi University Division of Metabolic Diseases and Nutrition developed this expert opinion consensus and expanded it to include metabolism specialists across Türkiye. A systematic literature review was performed, and the Delphi method was used to evaluate the results. Results: Seventeen conclusive questions were produced about clinical presentation, diagnosis, and treatment, and 14 reached a consensus. Consensus was reached that general hypotonia is one of the most important findings, and agreement was also achieved on the starting dose of treatment for presymptomatic patients. The contributors agreed that gene therapy is a good treatment option for IOPD in the future. Conclusion: The topics related to this consensus will help physicians in Türkiye and elsewhere with high incidence rates of IOPD,especially regarding diagnosis and treatment decisions.
- 20 June 2025
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 55 (3) , 585-594
Open AccessExpert opinion on clinical presentation, diagnosis and treatment of infantile onset pompe disease: a delphi study in Türkiye
Background/aim: Pompe disease (acid maltase deficiency, glycogen storage disease type II, OMIM #606800) is an autosomal recessive disorder characterized by lysosomal acid-α-glucosidase deficiency. The infantile-onset type of the disease is mainly characterized by cardiomegaly, hypotonia, and a high mortality rate. This study aimed to create a national consensus about infantile-onset Pompe disease (IOPD) to raise awareness among clinicians and standardize diagnosis and treatment approaches in Türkiye. Materials and methods: The Gazi University Division of Metabolic Diseases and Nutrition developed this expert opinion consensus and expanded it to include metabolism specialists across Türkiye. A systematic literature review was performed, and the Delphi method was used to evaluate the results. Results: Seventeen conclusive questions were produced about clinical presentation, diagnosis, and treatment, and 14 reached a consensus. Consensus was reached that general hypotonia is one of the most important findings, and agreement was also achieved on the starting dose of treatment for presymptomatic patients. The contributors agreed that gene therapy is a good treatment option for IOPD in the future. Conclusion: The topics related to this consensus will help physicians in Türkiye and elsewhere with high incidence rates of IOPD,especially regarding diagnosis and treatment decisions.
- 12 March 2025
- Published by Wiley in Pediatric Transplantation
- Vol. 29 (3) , e70067
Short and Long‐Term Outcomes of Liver Transplantation in Pediatric Patients With Inborn Errors of Metabolism: A Single‐Center Study
Background: Inborn errors of metabolism (IEMs) are inherited diseases causing significant morbidity and mortality, particularly in childhood. Liver transplantation (LT) can be curative or partially effective for these diseases. LT for IEMs has increased, making IEMs the second most common reason for pediatric LT after biliary atresia.Patients and Methods: Between 2001 and 2023, 50 pediatric patients with IEMs underwent LT at Başkent University, Ankara Hospital. Data collected retrospectively included diagnosis, gender, age of diagnosis, age of LT, LT indication, donor data, graft type, rejection episodes, post‐transplant complications, and clinical findings of the IEMs before and after LT. Treatment methods, follow‐up duration, and survival time were also recorded.Results: Of the 332 pediatric LT patients, 50 (15.1%) had IEMs, with three requiring re‐transplantations. Diagnoses included glycogen storage diseases (n = 11), tyrosinemia type 1 (n = 10), primary hyperoxaluria (n = 6), urea cycle disorders (n = 6), homozygous familial hypercholesterolemia (n = 4), propionic acidemia (n = 4), deoxyguanosine kinase deficiency (n = 3), maple syrup urine disease (n = 2), methylmalonic acidemia (n = 1), Niemann‐Pick disease type B (n = 1), alkaptonuria with unknown neonatal cholestasis (n = 1), and bile acid synthesis disorder (n = 1). The parental consanguinity rate was 74%. Living‐related donors provided organs for 48 (90.5%) patients. The mean age at LT was 75.3 ± 8.2 months (range: 5–218), with a follow‐up period of 82.1 ± 10.2 months (range:1 day–229 months). Survival rates at 1, 5, 10, and 15 years were 83.7%, 81%, 81%, and 70.9%, respectively.Conclusion: LT is an effective solution for children with IEM causing chronic organ failure and difficult to manage with medical treatment, showing a good long‐term prognosis.
- 12 March 2025
- Published by Wiley in Pediatric Transplantation
- Vol. 29 (3) , e70067
Short and Long‐Term Outcomes of Liver Transplantation in Pediatric Patients With Inborn Errors of Metabolism: A Single‐Center Study
Background: Inborn errors of metabolism (IEMs) are inherited diseases causing significant morbidity and mortality, particularly in childhood. Liver transplantation (LT) can be curative or partially effective for these diseases. LT for IEMs has increased, making IEMs the second most common reason for pediatric LT after biliary atresia.Patients and Methods: Between 2001 and 2023, 50 pediatric patients with IEMs underwent LT at Başkent University, Ankara Hospital. Data collected retrospectively included diagnosis, gender, age of diagnosis, age of LT, LT indication, donor data, graft type, rejection episodes, post‐transplant complications, and clinical findings of the IEMs before and after LT. Treatment methods, follow‐up duration, and survival time were also recorded.Results: Of the 332 pediatric LT patients, 50 (15.1%) had IEMs, with three requiring re‐transplantations. Diagnoses included glycogen storage diseases (n = 11), tyrosinemia type 1 (n = 10), primary hyperoxaluria (n = 6), urea cycle disorders (n = 6), homozygous familial hypercholesterolemia (n = 4), propionic acidemia (n = 4), deoxyguanosine kinase deficiency (n = 3), maple syrup urine disease (n = 2), methylmalonic acidemia (n = 1), Niemann‐Pick disease type B (n = 1), alkaptonuria with unknown neonatal cholestasis (n = 1), and bile acid synthesis disorder (n = 1). The parental consanguinity rate was 74%. Living‐related donors provided organs for 48 (90.5%) patients. The mean age at LT was 75.3 ± 8.2 months (range: 5–218), with a follow‐up period of 82.1 ± 10.2 months (range:1 day–229 months). Survival rates at 1, 5, 10, and 15 years were 83.7%, 81%, 81%, and 70.9%, respectively.Conclusion: LT is an effective solution for children with IEM causing chronic organ failure and difficult to manage with medical treatment, showing a good long‐term prognosis.
- Open Access
- 27 February 2025
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
Effect of empagliflozin treatment on laboratory and clinical findings of patients with glycogen storage disease type Ib: first study from Türkiye
Objectives: Empagliflozin has been used for the treatment of over 100 glycogen storage disease type Ib (GSDIb) patients worldwide since 2019. We aimed to evaluate the effect of empagliflozin treatment on the laboratory and clinical findings of patients with GSDIb in Türkiye. Methods: Included in this multicenter study were 10 patients with GSDIb, and whose demographic, clinical and laboratory data were analyzed retrospectively. Further data for the study were garnered through a survey of patients and caregivers to evaluate the effects of empagliflozin treatment on quality of life (QoL). Results: The mean age at which the empagliflozin treatment was started was 73.2 (4–239) months. The mean duration of empagliflozin treatment was 16.9 (8–39) months. Glucosuria was identified in eight (80 %) patients undergoing empagliflozin treatment, while urogenital infections were detected in six (60 %) and hypoglycemia in two (20 %). An analysis of neutrophil levels revealed increased absolute neutrophil counts following empagliflozin treatment. Skin and/or mucosal lesions were noted in nine (90 %) patients prior to the initiation of empagliflozin treatment, but persisted in only one patient following empagliflozin treatment (10 %) (p=0.008). Empagliflozin treatment resulted in a decrease in the frequency of hospitalizations due to infection (p=0.0015). Furthermore, 80 % of the patients reported positive impact on their well-being as a result of the empagliflozin treatment, and 70 % of parents reported improvement in physical performance and activities, in the sleep quality of both the patient and parents, and in mobility. Conclusions: This study revealed empagliflozin to be effective in improving the neutrophil counts of patients with GSD Ib and in enhancing the QoL of both the patients and their caregivers.
- 27 February 2025
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
Open AccessEffect of empagliflozin treatment on laboratory and clinical findings of patients with glycogen storage disease type Ib: first study from Türkiye
Objectives: Empagliflozin has been used for the treatment of over 100 glycogen storage disease type Ib (GSDIb) patients worldwide since 2019. We aimed to evaluate the effect of empagliflozin treatment on the laboratory and clinical findings of patients with GSDIb in Türkiye. Methods: Included in this multicenter study were 10 patients with GSDIb, and whose demographic, clinical and laboratory data were analyzed retrospectively. Further data for the study were garnered through a survey of patients and caregivers to evaluate the effects of empagliflozin treatment on quality of life (QoL). Results: The mean age at which the empagliflozin treatment was started was 73.2 (4–239) months. The mean duration of empagliflozin treatment was 16.9 (8–39) months. Glucosuria was identified in eight (80 %) patients undergoing empagliflozin treatment, while urogenital infections were detected in six (60 %) and hypoglycemia in two (20 %). An analysis of neutrophil levels revealed increased absolute neutrophil counts following empagliflozin treatment. Skin and/or mucosal lesions were noted in nine (90 %) patients prior to the initiation of empagliflozin treatment, but persisted in only one patient following empagliflozin treatment (10 %) (p=0.008). Empagliflozin treatment resulted in a decrease in the frequency of hospitalizations due to infection (p=0.0015). Furthermore, 80 % of the patients reported positive impact on their well-being as a result of the empagliflozin treatment, and 70 % of parents reported improvement in physical performance and activities, in the sleep quality of both the patient and parents, and in mobility. Conclusions: This study revealed empagliflozin to be effective in improving the neutrophil counts of patients with GSD Ib and in enhancing the QoL of both the patients and their caregivers.
- Open Access
Three-Country Snapshot of Ornithine Transcarbamylase Deficiency
X-linked ornithine transcarbamylase deficiency (OTCD) is the most common urea cycle defect. The disease severity ranges from asymptomatic carrier state to severe neonatal presentation with hyperammonaemic encephalopathy. We audited the diagnosis and management of OTCD, using an online 12-question-survey that was sent to 75 metabolic centres in Turkey, France and the UK. Thirty-nine centres responded and 495 patients were reported in total. A total of 208 French patients were reported, including 71 (34%) males, 86 (41%) symptomatic and 51 (25%) asymptomatic females. Eighty-five Turkish patients included 32 (38%) males, 39 (46%) symptomatic and 14 (16%) asymptomatic females. Out of the 202 UK patients, 66 (33%) were male, 83 (41%) asymptomatic and 53 (26%) symptomatic females. A total of 19%, 12% and 7% of the patients presented with a neonatal-onset phenotype in France, Turkey and the UK, respectively. Vomiting, altered mental status and encephalopathy were the most common initial symptoms in all three countries. While 69% in France and 79% in Turkey were receiving protein restriction, 42% were on a protein-restricted diet in the UK. A total of 76%, 47% and 33% of patients were treated with ammonia scavengers in Turkey, France and the UK, respectively. The findings of our audit emphasize the differences and similarities in manifestations and management practices in three countries.
Open AccessThree-Country Snapshot of Ornithine Transcarbamylase Deficiency
X-linked ornithine transcarbamylase deficiency (OTCD) is the most common urea cycle defect. The disease severity ranges from asymptomatic carrier state to severe neonatal presentation with hyperammonaemic encephalopathy. We audited the diagnosis and management of OTCD, using an online 12-question-survey that was sent to 75 metabolic centres in Turkey, France and the UK. Thirty-nine centres responded and 495 patients were reported in total. A total of 208 French patients were reported, including 71 (34%) males, 86 (41%) symptomatic and 51 (25%) asymptomatic females. Eighty-five Turkish patients included 32 (38%) males, 39 (46%) symptomatic and 14 (16%) asymptomatic females. Out of the 202 UK patients, 66 (33%) were male, 83 (41%) asymptomatic and 53 (26%) symptomatic females. A total of 19%, 12% and 7% of the patients presented with a neonatal-onset phenotype in France, Turkey and the UK, respectively. Vomiting, altered mental status and encephalopathy were the most common initial symptoms in all three countries. While 69% in France and 79% in Turkey were receiving protein restriction, 42% were on a protein-restricted diet in the UK. A total of 76%, 47% and 33% of patients were treated with ammonia scavengers in Turkey, France and the UK, respectively. The findings of our audit emphasize the differences and similarities in manifestations and management practices in three countries.
- 24 December 2021
- Published by Oxford University Press (OUP) in Brain
- Vol. 145 (11) , 3985-3998
Bi-allelic loss-of-function OBSCN variants predispose individuals to severe recurrent rhabdomyolysis
Rhabdomyolysis is the acute breakdown of skeletal myofibres in response to an initiating factor, most commonly toxins and over exertion. A variety of genetic disorders predispose to rhabdomyolysis through different pathogenic mechanisms, particularly in patients with recurrent episodes. However, most cases remain without a genetic diagnosis. Here we present six patients who presented with severe and recurrent rhabdomyolysis, usually with onset in the teenage years; other features included a history of myalgia and muscle cramps. We identified 10 bi-allelic loss-of-function variants in the gene encoding obscurin (OBSCN) predisposing individuals to recurrent rhabdomyolysis. We show reduced expression of OBSCN and loss of obscurin protein in patient muscle. Obscurin is proposed to be involved in sarcoplasmic reticulum function and Ca2+ handling. Patient cultured myoblasts appear more susceptible to starvation as evidenced by a greater decreased in sarcoplasmic reticulum Ca2+ content compared to control myoblasts. This likely reflects a lower efficiency when pumping Ca2+ back into the sarcoplasmic reticulum and/or a decrease in Ca2+ sarcoplasmic reticulum storage ability when metabolism is diminished. OSBCN variants have previously been associated with cardiomyopathies. None of the patients presented with a cardiomyopathy and cardiac examinations were normal in all cases in which cardiac function was assessed. There was also no history of cardiomyopathy in first degree relatives, in particular in any of the carrier parents. This cohort is relatively young, thus follow-up studies and the identification of additional cases with bi-allelic null OBSCN variants will further delineate OBSCN-related disease and the clinical course of disease.
- 24 December 2021
- Published by Oxford University Press (OUP) in Brain
- Vol. 145 (11) , 3985-3998
Bi-allelic loss-of-function OBSCN variants predispose individuals to severe recurrent rhabdomyolysis
Rhabdomyolysis is the acute breakdown of skeletal myofibres in response to an initiating factor, most commonly toxins and over exertion. A variety of genetic disorders predispose to rhabdomyolysis through different pathogenic mechanisms, particularly in patients with recurrent episodes. However, most cases remain without a genetic diagnosis. Here we present six patients who presented with severe and recurrent rhabdomyolysis, usually with onset in the teenage years; other features included a history of myalgia and muscle cramps. We identified 10 bi-allelic loss-of-function variants in the gene encoding obscurin (OBSCN) predisposing individuals to recurrent rhabdomyolysis. We show reduced expression of OBSCN and loss of obscurin protein in patient muscle. Obscurin is proposed to be involved in sarcoplasmic reticulum function and Ca2+ handling. Patient cultured myoblasts appear more susceptible to starvation as evidenced by a greater decreased in sarcoplasmic reticulum Ca2+ content compared to control myoblasts. This likely reflects a lower efficiency when pumping Ca2+ back into the sarcoplasmic reticulum and/or a decrease in Ca2+ sarcoplasmic reticulum storage ability when metabolism is diminished. OSBCN variants have previously been associated with cardiomyopathies. None of the patients presented with a cardiomyopathy and cardiac examinations were normal in all cases in which cardiac function was assessed. There was also no history of cardiomyopathy in first degree relatives, in particular in any of the carrier parents. This cohort is relatively young, thus follow-up studies and the identification of additional cases with bi-allelic null OBSCN variants will further delineate OBSCN-related disease and the clinical course of disease.
- Open Access
- 1 January 2021
- Published by XMLink in Pediatric Gastroenterology, Hepatology & Nutrition
- Vol. 24 (5) , 483-491
The Relationship between Daily Fructose Consumption and Oxidized Low-Density Lipoprotein and Low-Density Lipoprotein Particle Size in Children with Obesity
Gungor A, et al. Pediatr Gastroenterol Hepatol Nutr. 2021 Sep;24(5):483-491. https://doi.org/10.5223/pghn.2021.24.5.483
- 1 January 2021
- Published by XMLink in Pediatric Gastroenterology, Hepatology & Nutrition
- Vol. 24 (5) , 483-491
Open AccessThe Relationship between Daily Fructose Consumption and Oxidized Low-Density Lipoprotein and Low-Density Lipoprotein Particle Size in Children with Obesity
Gungor A, et al. Pediatr Gastroenterol Hepatol Nutr. 2021 Sep;24(5):483-491. https://doi.org/10.5223/pghn.2021.24.5.483
- 1 January 2021
- Published by Hacettepe University Institute of Child Health in The Turkish Journal of Pediatrics
- Vol. 63 (4) , 716-720
Severe isolated sulfide oxidase deficiency with a novel mutation
Background. Isolated sulfite oxidase deficiency (ISOD), caused by mutations in SUOX gene, is an autosomal recessive disease manifesting with early onset seizures, developmental delay, microcephaly, and spasticity. It mimics hypoxic-ischemic encephalopathy (HIE) in the neonatal period and is characterized by progressive severe neurological impairment due to accumulation of toxic metabolites. Case. This report presents a late diagnosed male patient with ISOD manifesting with neonatal-onset seizures, developmental delay, microcephaly, and spastic quadriplegia. Brain magnetic resonance imaging of the patient showed bilateral subcortical multi-cystic encephalomalacia involving bilateral parieto-occipital regions. A novel homozygous c.590_595delAGCCTC in-frame deletion in SUOX gene was identified in the patient, while both parents were heterozygous for that mutation. Conclusion. The mutation identified in our patient causes severe ISOD. Early diagnosis of ISOD is essential for accurate genetic counseling and achieving prenatal diagnosis. Screening for urinary sulfite in patients with neonatal or early infantile onset seizures, developmental delay, microcephaly and cystic encephalomalacia in neuroimaging mimicking HIE helps in early diagnosis.
- 1 January 2021
- Published by Hacettepe University Institute of Child Health in The Turkish Journal of Pediatrics
- Vol. 63 (4) , 716-720
Severe isolated sulfide oxidase deficiency with a novel mutation
Background. Isolated sulfite oxidase deficiency (ISOD), caused by mutations in SUOX gene, is an autosomal recessive disease manifesting with early onset seizures, developmental delay, microcephaly, and spasticity. It mimics hypoxic-ischemic encephalopathy (HIE) in the neonatal period and is characterized by progressive severe neurological impairment due to accumulation of toxic metabolites. Case. This report presents a late diagnosed male patient with ISOD manifesting with neonatal-onset seizures, developmental delay, microcephaly, and spastic quadriplegia. Brain magnetic resonance imaging of the patient showed bilateral subcortical multi-cystic encephalomalacia involving bilateral parieto-occipital regions. A novel homozygous c.590_595delAGCCTC in-frame deletion in SUOX gene was identified in the patient, while both parents were heterozygous for that mutation. Conclusion. The mutation identified in our patient causes severe ISOD. Early diagnosis of ISOD is essential for accurate genetic counseling and achieving prenatal diagnosis. Screening for urinary sulfite in patients with neonatal or early infantile onset seizures, developmental delay, microcephaly and cystic encephalomalacia in neuroimaging mimicking HIE helps in early diagnosis.